Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts

JAMA Internal Medicine

Volumn 176, Issue 6, 2016, Pages 763-768

  Yeh, James S ^a   Franklin, Jessica M ^a   Avorn, Jerry ^a   Landon, Joan ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; ATORVASTATIN PLUS EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SIMVASTATIN PLUS SITAGLIPTIN; GENERIC DRUG; PRESCRIPTION DRUG;

ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; HUMAN; MASSACHUSETTS; MEDICAID; MEDICAL FEE; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; CLINICAL PRACTICE; ECONOMICS; FEMALE; HEALTH CARE COST; HYPERCHOLESTEROLEMIA; MALE; UNITED STATES;

CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; DRUGS, GENERIC; FEMALE; HEALTH EXPENDITURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MASSACHUSETTS; MEDICARE PART D; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84973469338     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.1709     Document Type: Article

References (27)

1. Campbell EG. Doctors and drug companies-scrutinizing influential relationships. N Engl J Med. 2007;357(18):1796-1797.
2. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Changing interactions between physician trainees and the pharmaceutical industry: A national survey. J Gen Intern Med. 2013; 28(8):1064-1071.
3. Campbell EG, Rao SR, DesRoches CM, et al. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med. 2010;170(20):1820-1826.
4. Agrawal S, Brennan N, Budetti P. The Sunshine Act-effects on physicians. N Engl J Med. 2013;368 (22):2054-2057.
5. Chimonas S, Rozario NM, Rothman DJ. Show us the money: lessons in transparency from state pharmaceutical marketing disclosure laws. Health Serv Res. 2010;45(1):98-114.
6. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: Early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007;297 (11):1216-1223.
7. Grande D. Limiting the influence of pharmaceutical industry gifts on physicians: self-regulation or government intervention? J Gen Intern Med. 2010;25(1):79-83.
8. Kirschner NM, Sulmasy LS, Kesselheim AS. Health policy basics: The Physician Payment Sunshine Act and the Open Payments program. Ann Intern Med. 2014;161(7):519-521.
9. Pharma Pushes CMS for Transparency on Sunshine Database. Again. 2014; http://blogs.wsj.com/pharmalot/2014/09/24/pharma-pushes-cms-for-transparency-on-sunshine-database-again/. Accessed December 9, 2015.
10. Ratain MJ. Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy. J Clin Oncol. 2014;32(22):2293-2295.
11. Amid the Sunshine, Controversy Lingers: The Release of CMS's "Open Payments" System. 2014; http://www.forbes.com/sites/insider/2014/10/01/amid-the-sunshine-controversy-lingers-the-release-of-cmss-open-payments-system/. Accessed December 29, 2015.
12. Wilson M. Is transparency really a panacea? J R Soc Med. 2014;107(6):216-217.
13. Pham-Kanter G. Act II of the Sunshine Act. PLoS Med. 2014;11(11):e1001754.
14. Carlat D. Exploring the link between industry payments to doctors and prescribing habits. BMJ. 2014;349:g6651.
15. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8(1):13-20.
16. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992;102(1):270-273.
17. Lieb K, Scheurich A. Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One. 2014;9(10):e110130.
18. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283 (3):373-380.
19. King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ. 2013;346:f264.
20. Harrington RA, Califf RM. There is a role for industry-sponsored education in cardiology. Circulation. 2010;121(20):2221-2227.
21. Rosenbaum L. Beyond moral outrage-weighing the trade-offs of COI regulation. N Engl J Med. 2015;372(21):2064-2068.
22. Engelberg J, Parsons CA, Tefft N. Financial Conflicts of Interest in Medicine. http://papers.ssrn.com/sol3/papers.cfm?abstract-id=2297094. Accessed December 29, 2015 2014.
23. Pharmaceutical Code of Conduct. http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/healthcare-quality/pharm-code-of-conduct/. Accessed December 29, 2015.
24. Propublica. Propublica Prescriber Checkup Methodology. https://www.propublica.org/article/how-we-analyzed-medicares-drug-data-long-methodology. Accessed February 17, 2016.
25. Gagne JJ, Choudhry NK, Kesselheim AS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: A cohort study. Ann Intern Med. 2014;161(6):400-407.
26. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-337.
27. Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When choosing statin therapy: The case for generics. JAMA Intern Med. 2013;173(3): 229-232.